Intarcia Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Intarcia Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0486
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc is a biopharmaceutical company that discovers, develops and commercializes drug therapies. The company’s product candidates include ITCA 650, used for the treatment of type II diabetes and obesity. It offers technology platform that helps to develop proprietary formulations and evaluation of drug candidates through formulations. Intarcia uses Medici drug delivery system, a subcutaneous delivery system to maintain the optimal level of highly potent small molecules in the human body such as proteins, antibody fragments and peptides. The company operates manufacturing facility in Hayward. Intarcia is headquartered in Boston, Massachusetts, the US.

Intarcia Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Intarcia Therapeutics Raises USD75 Million in Financing 12
Phoundry Pharma Raises USD0.5 Million in Seed Financing 13
Intarcia Therapeutics Raises US$200 Million In Venture Financing 14
Intarcia Therapeutics Raises US$210 Million In Venture Financing 16
Intarcia Therapeutics Raises USD0.7 Million in Venture Financing 18
Intarcia Therapeutics Raises Additional US$5.5 Million In Venture financing 19
Intarcia Therapeutics Raises US$7.3 Million In Venture financing 20
Partnerships 22
Intarcia Therapeutics Enters into Co-Development Agreement with Numab 22
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 23
Licensing Agreements 24
Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 24
Intarcia Therapeutics Plans To License Drug-Formulation Technology 25
Equity Offering 26
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 26
Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 27
Debt Offering 28
Intarcia Therapeutics Raises USD300 Million in Financing 28
Acquisition 29
Intarcia Therapeutics Acquires Phoundry Pharma 29
Intarcia Therapeutics Inc – Key Competitors 30
Intarcia Therapeutics Inc – Key Employees 31
Intarcia Therapeutics Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Product News 33
09/15/2017: New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes 33
Product Approvals 34
Feb 03, 2017: Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intarcia Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intarcia Therapeutics Raises USD75 Million in Financing 12
Phoundry Pharma Raises USD0.5 Million in Seed Financing 13
Intarcia Therapeutics Raises US$200 Million In Venture Financing 14
Intarcia Therapeutics Raises US$210 Million In Venture Financing 16
Intarcia Therapeutics Raises USD0.7 Million in Venture Financing 18
Intarcia Therapeutics Raises Additional US$5.5 Million In Venture financing 19
Intarcia Therapeutics Raises US$7.3 Million In Venture financing 20
Intarcia Therapeutics Enters into Co-Development Agreement with Numab 22
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 23
Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 24
Intarcia Therapeutics Plans To License Drug-Formulation Technology 25
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 26
Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 27
Intarcia Therapeutics Raises USD300 Million in Financing 28
Intarcia Therapeutics Acquires Phoundry Pharma 29
Intarcia Therapeutics Inc, Key Competitors 30
Intarcia Therapeutics Inc, Key Employees 31
Intarcia Therapeutics Inc, Other Locations 32
Intarcia Therapeutics Inc, Subsidiaries 32

List of Figures
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intarcia Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Intarcia Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Daxor Corp (DXR):企業の財務・戦略的SWOT分析
    Daxor Corp (DXR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mehler Vario System GmbH:企業の戦略・SWOT・財務情報
    Mehler Vario System GmbH - Strategy, SWOT and Corporate Finance Report Summary Mehler Vario System GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Equipos Nucleares SA:企業の戦略的SWOT分析
    Equipos Nucleares SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • OncoSec Medical Inc (ONCS):企業の財務・戦略的SWOT分析
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company. The company offers services to stimulate body’s immune system and attack cancer. Its lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor th …
  • Swire Pacific Ltd:企業の戦略・SWOT・財務情報
    Swire Pacific Ltd - Strategy, SWOT and Corporate Finance Report Summary Swire Pacific Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Allied Hotel Properties Inc.:戦略・SWOT・企業財務分析
    Allied Hotel Properties Inc. - Strategy, SWOT and Corporate Finance Report Summary Allied Hotel Properties Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • JP Elektroprivreda BiH d.d. Sarajevo (JPESR):企業の財務・戦略的SWOT分析
    JP Elektroprivreda BiH d.d. Sarajevo (JPESR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Avantec Vascular Corp:製品パイプライン分析
    Summary Avantec Vascular Corp (Avantec Vascular), a subsidiary of Goodman Co Ltd is a medical device company that develops cardiovascular interventional and peripheral vascular devices. The company's products comprise balloon catheter, aspiration catheter, device delivery system, micro catheter, gui …
  • LinkedIn Corp:企業の戦略的SWOT分析
    LinkedIn Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Corvidia Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Corvidia Therapeutics Inc (Corvidia Therapeutics) is a clinical stage biotechnology company that develops cardiovascular and cardio-renal therapies leveraging functional genomics. The company develops COR-001 for the treatment of chronic kidney disease on dialysis (under phase 2 stage), and …
  • Ceapro Inc (CZO)-製薬・医療分野:企業M&A・提携分析
    Summary Ceapro Inc (Ceapro) is a biotechnology company which focuses on the development of extraction technology for use in the production of extracts and active ingredients from oats and other renewable plant resources. These extracts find application in therapeutic products for both humans and ani …
  • Aptose Biosciences Inc (APTO):製薬・医療:M&Aディール及び事業提携情報
    Summary Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion dia …
  • Alabama Municipal Electric Authority:企業の発電所・SWOT分析2018
    Alabama Municipal Electric Authority - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Heliatek GmbH-エネルギー分野:企業M&A・提携分析
    Summary Heliatek GmbH (Heliatek) is a solar energy company that manufactures and constructs organic photovoltaics. The company manufactures modules on flexible substrates utilizing a roll-to-roll production process. Its products include OPV oligomers, OPV polymers, and OPV dye-sensitized solar cells …
  • Greensmith Energy Management Systems LLC:企業の戦略的SWOT分析
    Greensmith Energy Management Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Black & Veatch Corp:企業の戦略的SWOT分析
    Black & Veatch Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • The Bangchak Petroleum PCL (BCP):石油・ガス:M&Aディール及び事業提携情報
    Summary The Bangchak Petroleum PCL (Bangchak) is an oil and gas company. It carries out import of crude oil from both indigenous and overseas sources, and refines it into finished petroleum products. Its refinery produces gasoline, gasohol and diesel products. The company markets its petroleum produ …
  • Hillenbrand Inc (HI):企業の財務・戦略的SWOT分析
    Hillenbrand Inc (HI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • TenCate Advanced Armour:企業の戦略・SWOT・財務分析
    TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report Summary TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Genting Plantations Berhad (GENP):企業の財務・戦略的SWOT分析
    Genting Plantations Berhad (GENP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆